To evaluate the association between renal tumour complexity and outcomes in a large cohort of patients undergoing percutaneous cryoablation (PCA).
Introduction
Although associated with a benefit in renal function preservation [1] [2] [3] , partial nephrectomy can be technically challenging depending on the anatomical features of the tumour. Increasing anatomical tumour complexity, as quantified by the R.E.N.A.L. [4] and PADUA [5] nephrometry score (NS) systems, is associated with an increased risk of complications and worse renal function outcomes [4] [5] [6] . In patients without an absolute indication for partial nephrectomy, tumour complexity may influence surgeons towards performing a radical nephrectomy instead [7] .
When nephron-sparing is desired, percutaneous renal ablation may be considered a therapeutic alternative [8] ; however, the impact of anatomical tumour complexity on percutaneous ablation outcomes requires further characterization. Data on complications are based on small studies [9] [10] [11] , studies on local recurrence appear conflicting [11] [12] [13] , and data on renal function outcomes and cancerspecific mortality (CSM) are lacking. While we have previously reported on the impact of tumour complexity in a cohort undergoing percutaneous radiofrequency ablation (RFA) and percutaneous cryoablation (PCA) [12] , a detailed analysis on the impact of tumour complexity on renal function and CSM was not performed. Moreover, it is necessary to assess a pure cohort undergoing PCA, because this technique has emerged to be more efficacious in treating complex tumours, while percutaneous RFA is now reserved for small peripheral tumours [14, 15] .
Our objective was to evaluate comprehensively the association between R.E.N.A.L. NS and post-procedural complications, renal function outcomes, and oncological outcomes in patients undergoing PCA. Given that the anatomical tumour features that predict partial nephrectomy difficulty may not be the same as those that render PCA challenging, we hypothesized that no association or a weak association between NS and outcomes would be observed.
Methods

Study Design and Participants
Institutional review board ethics approval was obtained for this retrospective cohort study. Patients without nodal or distant metastases who underwent PCA between 1 March 2003 and 31 December 2015 for one or more clinically localized renal tumours were identified using our prospectively maintained percutaneous ablation registry. Exclusion criteria included salvage procedures, inherited tumour syndromes, and treatment in a transplanted kidney.
Treatment
Patients were initially seen by a urologist to determine the optimum management strategy for their renal mass. If they opted for ablation, a referral was then made to an interventional radiologist to evaluate feasibility and suitability [12] . PCA was performed under general anaesthesia. Unless obtained beforehand, simultaneous renal mass biopsy was incorporated as routine practice, particularly in later years. Cryoprobes were placed under ultrasonography and/or CT guidance, with 1-2-cm spacing in a configuration to achieve an ice ball covering the entire tumour with at least a 3-5-mm margin. A typical freeze-passive thaw-refreeze cryoablation cycle was performed, with duration of freezing based on coverage of the tumour by the ice ball using CT monitoring every 2-4 min. When needed in selected cases based on tumour size and location, adjunctive procedures were performed. Such procedures included hydro-displacement of the adjacent bowel using image-guided saline instillation [16] , pre-ablation selective arterial embolization of tumours ≥5 cm specifically to reduce bleeding risk [17] , and retrograde pyeloperfusion via an externalized ureteric stent for ureteric protection [18] .
Exposure and Outcomes
Preoperative imaging was evaluated by two interventional radiologists to determine R.E.N.A.L. NS for each tumour [4] . Tumours were classified as having low (4-6), intermediate (7) (8) (9) and high (10-12) NS. If patients underwent multiple separate procedures, then they were grouped according to the tumour(s) treated during their first procedure. If multiple tumours were treated during the same procedure, then the most complex tumour was used for analysis.
Patients were seen in the urology clinic 3 months after treatment, and underwent renal function assessment and cross-sectional imaging. After this, patients were recommended to have similar assessment at 6, 12, 18, 24 and 36 months, with yearly follow-up thereafter.
Post-procedural inpatient complications were classified according to the Clavien-Dindo system for each procedure [19] . Prolonged length of stay was defined as >2 nights. Renal function outcomes were analysed per procedure. Serum creatinine was used to calculate estimate GFR (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [20] . Local treatment failure was assessed per tumour and was defined as either technical failure (failure of the ablation ice ball to extend beyond the tumour margin on monitoring CT imaging during the procedure) or local recurrence (an enhancing or enlarging soft tissue nodule in or around the ablation zone on cross-sectional imaging performed after treatment). Metastases, CSM and all-cause mortality (ACM) were evaluated on a per-patient basis starting from the date of their first treatment. Patients were followed until death, with a maximum follow-up until 1 January 2016. Censoring occurred at the time of last imaging study for local recurrence, and at the time of last clinical follow-up for CSM and ACM.
Statistical Analyses
Bivariate comparisons between NS groups were performed using the Wilcoxon rank sum test for continuous variables, and Pearson's chi-squared and Fisher's exact tests for categorical variables. The median follow-up was determined using the reverse Kaplan-Meier method [21] . Kaplan-Meier analyses were performed for overall, cancer-specific and local failure-free survival. Unadjusted and multivariable-adjusted linear, logistic and Cox proportional hazards regression models were used to evaluate the associations between NS and continuous, binary and time-to-event outcomes, respectively. Multivariable models adjusted for the following a priori selected covariates: age, baseline eGFR, and year of treatment. Linear regression models for percent drop in eGFR at last follow-up were additionally adjusted for time between ablation and eGFR measurement. For CSM and metastasis, analyses were conducted in the subset of patients If an association between NS and a given outcome was statistically and clinically significant, an additional analysis was performed with individual R.E.N.A.L. NS components in the model in order to understand which feature(s) were driving the observed association. Predictive ability was assessed by evaluating the area under the receiver-operating characteristic curve. A subset analysis was also performed in patients with a single tumour who only underwent a single procedure.
Analyses were carried out using SAS v9.3 (SAS Institute Inc., Cary, NC, USA). All tests were two-sided, with P values <0.05 taken to indicate statistical significance. No adjustments were made for multiple comparisons [22] .
Results
The final cohort included 618 tumours treated during 580 procedures performed in 565 patients (Fig. S1 ). Cohort characteristics are summarized in Table 1 . The median (interquartile range [IQR]) patient age was 71 (73.77) years, and 177 (31%) were women. The median (range) tumour size was 3.0 (0.7-8.9) cm. The majority were biopsy-proven RCC (n = 391, 63%), while 41 (7%) were not biopsied. Hydrodisplacement, retrograde pyeloperfusion, and pre-ablation selective tumour angioembolization were performed in 208 (36%), 70 (12%), and 41 (7%) cases, respectively. The median (IQR) follow-up was 34 (13-66) months.
Complications and Length of Stay
The median (range) length of stay was 1 (0-37) night, while prolonged length of stay (>2 nights) occurred after 40 (7%) procedures. There were 87 (15%) procedures with associated complications, of which 34 (6%), eight (1%), and zero (0%) were classified as Clavien 3, 4 and 5, respectively. Complications, Clavien 3-5 complications, and prolonged length of stay were more frequent with higher NS (all P < 0.001; Table 2 ).
In fact, on multivariable logistic regression analyses (Table 3) , each additional point in tumour NS was independently associated with increased risk of any complication (odds ratio [OR] 1.3; 95% CI 1.2-1.5; P < 0.001), Clavien 3-5 complication (OR 1.4; 95% CI 1.1-1.7; P = 0.003), and prolonged hospital stay (OR 1.6; 95% CI 1.2-2.0; P < 0.001) after PCA. Specifically, treatment of high NS tumours was associated with a 5.5-fold (95% CI 2.8-10.9; P < 0.001) increase in odds of any complication, a 5.2-fold (95% CI 2.2-12.3; P < 0.001) increase in odds of a Clavien 3-5 complication, and an 8.4-fold (95% CI 3.3-21.2; P < 0.001) increase in odds of prolonged hospital stay compared with procedures treating low NS tumours.
When evaluating individual NS components (Table S1 ), the tumour diameter score was the component most strongly associated with odds of any complication (OR 3.4; 95% CI 2.2-5.2; P < 0.001), Clavien 3-5 complications (OR 3.2; 95% CI 1.8-5.5; P < 0.001), and prolonged stay (OR 11.6; 95% CI 6.0-22.2; P < 0.001). Location relative to polar lines was also associated with complication risk (OR 1.4; 95% CI 1.0-1.9; P = 0.04), while the exophytic-endophytic score was also associated with prolonged stay (OR 1.9, 95% CI 1.1-3.3; P = 0.03). Finally, in multivariable models with age, year of treatment, baseline eGFR and tumour size as predictors, the addition of NS did not meaningfully improve the predictive ability of models for risk of complications overall (area under the curve 0.704 vs 0.695; log likelihood test P = 0.005) and risk of Clavien 3-5 complications (area under the curve 0.747 vs 0.734; log likelihood test P = 0.05).
Renal Function Outcomes
The median (IQR) drop in eGFR was 5 (0, 15)% at discharge and 9 (0, 22)% at last follow-up, relative to baseline. In bivariate analyses, the drop in eGFR relative to baseline was greater at discharge (P = 0.01) and at last follow-up (P = 0.01) in higher NS groups (Table 2) . Differences between NS groups in new-onset stage 3-5 chronic kidney disease (CKD; P > 0.99) or end-stage renal disease (stage 5 CKD; P = 0.49) did not reach statistical significance.
In multivariable linear regression analyses (Table 3) , each additional point in the NS was associated with an additional 1.2% (95% CI 0.4-2.1; P = 0.005) and 1.3% (95% CI 0.4-2.1; P = 0.03) decline in eGFR at discharge and at last follow-up, respectively. Procedures on tumours with a high NS were associated with a 6.4% (95% CI 1.0-11.7; P = 0.02) and 7.3% (95% CI 0.2-14.5; P = 0.04) additional decline in eGFR at discharge and at last follow-up, respectively, compared with procedures on low NS tumours. The association between NS and new-onset stage 3-5 CKD did not reach statistical significance (OR [per 1 point] = 1.1, 95% CI 0.9-1.2; P = 0.64).
Oncological Outcomes
There were 14 tumours (2%) that failed locally and 111 (19.6%) patients who died overall. Among patients with biopsy-proven RCC, 11 (3%) developed metastases and eight (2%) died from RCC. There were no differences between NS groups in bivariate analyses (Table 2) for local failure (P = 0.32), metastasis (P > 0.99), CSM (P = 0.88), or ACM (P = Among patients with tumours that were biopsy-proven RCC (n = 391).
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© 2017 The Authors BJU International © 2017 BJU International 0.37). NS was not associated with local failure-free, cancerspecific, or overall survival in Kaplan-Meier (Fig. 1) and Cox regression (Table 3) analyses. When evaluating local failure and ACM in the subset of patients with biopsy-proven RCC, results on Kaplan-Meier (Fig. S2) and Cox regression analyses (Table S2) were similar to the main analysis ( Fig. 1 and Table 3 ).
In the subset analysis of patients with a single tumour undergoing a single procedure, effect estimates for the associations between NS and complications, length of stay, renal function outcomes, and oncological outcomes were similar to the main analysis presented in Table 3 (data not shown).
Discussion
To our knowledge, the present comprehensive study of the impact of anatomical tumour complexity represents the largest PCA series reported to date. The study validates smaller studies that have shown an association between renal tumour complexity and risk of complications [9] [10] [11] 13] , and adds that this association is driven primarily by tumour size. The present study is the first, to our knowledge, to characterize a statistically significant but clinically insignificant association between higher NS and poorer renal function outcomes. Finally, we found that the risk of local failure and CSM was low, regardless of tumour complexity, in (7-9) 2.8 (À0.6 to 6.3) 0. patients undergoing PCA, which may add clarity to the existing literature [11] [12] [13] .
Nephron-sparing has rightly become an increasingly important consideration in the management of renal tumours. Diminished eGFR is associated with risk of death, cardiovascular events and hospitalization [3] . Given that anatomical tumour complexity may deter many surgeons from the challenge of nephron-sparing surgery [7] , percutaneous ablation may be considered if nephron-sparing is desired; however, it is essential to understand whether anatomical tumour complexity affects percutaneous ablation outcomes in the same way as surgery in order to make an informed decision on this issue.
Our study focused on PCA because it has become the primary treatment method for complex renal tumours at our institution [23] . PCA is more effective for treating larger and central tumours than RFA because multiple cryoprobes can generate a large confluent lethal ice ball which is also less susceptible to thermal 'sink effect' centrally in the kidney [24] . Conversely, percutaneous RFA is associated with an increased risk of technical failure in larger (≥3 cm) and central tumours [12, 15] , as well as worse metastasis-free survival in cT1 tumours [25] .
Most studies are generally in agreement with the association between tumour NS and complications [9] [10] [11] [12] [13] , although one study of patients undergoing RFA reported no association [26] ; however, we do not believe that complication risk on its own should be a reason to avoid PCA in anatomically complex tumours. It should be noted that several of the patients with complex renal tumours in our cohort were deemed unsuitable for partial nephrectomy; therefore, PCA may be the best option if a nephron-sparing approach is desired.
A novel finding in the present study is that the association between NS and complications appears to be primarily driven by tumour size, while the other NS components are less important. An association between tumour size and complications has been demonstrated previously and is probably related, in part, to the greater number of cryoprobes required to treat such larger tumours [27] . Individual anatomical tumour features might therefore be helpful in Months 0  20  40  60  80  221  131  64  41  16  277  186  119  60  26  62  36  19 In the present study, increasing tumour NS was associated with a statistically significant but clinically insignificant additional renal function decline after PCA. This is consistent with the current understanding of PCA. Most data suggest that PCA induces a minor decline in renal function related to the need to freeze a margin of normal tissue [28] .
While studies evaluating the association between tumour complexity and local failure may appear conflicting [11] [12] [13] , the discrepancies may be explained by the inclusion of patients undergoing RFA. Given the challenge in treating large and/or central tumours with RFA, the inclusion of these patients may drive observed associations. For example, Camacho et al. [13] and our group [12] have separately reported an association between higher NS and risk of local failure in mixed cohorts of patients undergoing percutaneous RFA and PCA. Meanwhile, in a pure cohort of patients undergoing PCA only, Blute et al. [11] found no association between NS and local failure. Similarly, local failure risk was low in our pure PCA cohort, regardless of tumour complexity.
Finally, very few patients in the present study developed metastases or died from RCC. By contrast, there was a larger proportion of non-cancer deaths, probably reflecting the underlying comorbidity of patients who underwent PCA because they were not suitable candidates for surgery.
The present study has several limitations. First, as in any observational study, we cannot exclude selection bias or unmeasured confounding. Patients undergoing PCA have been carefully selected as appropriate candidates for this treatment and are inherently different from patients treated surgically. Further studies are needed to delineate optimum selection criteria. Second, patients did not routinely undergo biopsy in early years of the study; however, this is an unlikely source of bias in evaluating the association between NS and oncological outcomes because the subgroup analyses of patients with biopsy-proven RCC were similar to our main analysis. Third, it is possible that a subtle association between higher NS and local failure was missed because of the low number of recurrences; however, given the low absolute risk of local failure, such an association may not be clinically important. Fourth, aging and comorbidities may have contributed to renal function decline over time, and their relative contributions over time are difficult to discern. Fifth, further follow-up will be required to confirm long-term oncological efficacy and renal function outcomes. Finally, caution should be applied in generalizing our study findings to low-volume settings. Procedures are being performed in a tertiary referral centre with multidisciplinary management including subspecialty-trained urologists and radiologists, allowing aggressive care while achieving quite favourable oncological outcomes. Providers with less experience should be cautious in treating complex tumours with PCA.
In conclusion, when using PCA, anatomical tumour complexity is associated with an increased risk of complications that is primarily driven by tumour size. The other components of the NS, which are important predictors for partial nephrectomy complications, may carry less importance for PCA. Greater tumour complexity is also associated with a statistically significant, but minor in magnitude, additional decline in renal function after PCA. Risks for local failure and CSM after PCA are low, regardless of tumour complexity.
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